A Study of [14C]-LY4065967 in Healthy Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Eli Lilly and Company
Study ID
NCT07039045
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study. The study will last about 58 days for participants in Part 1 and about 60 days for participants in Part 2.

Key Dates

Start date
Jun 23, 2025
Status verified
Sep 2025
Primary completion
Aug 16, 2025
Completion
Aug 16, 2025

Study Design

Enrollment
16 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: [14C]-LY4065967 Part 1
    A single dose containing \[14C\]-LY4065967.
  • Experimental: LY4065967 Part 2
    A single dose of LY4065967 followed by a single dose of \[14C\]-LY4065967.

Primary Outcome Measure

Part 1: Percentage of Total Radioactive Dose in Urine and Fecal Excretion [ Time Frame: Baseline through Study Completion (21 days) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitMadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit· Madison, WI

Related Studies